Rheumatoid arthritis and the challenge of using nanoparticles for its treatment

Citations of this article
Mendeley users who have this article in their library.


Rheumatoid arthritis is the most common autoimmune disease that affects the joints. The cause of the disease is unknown, many studies proposed hypothesis about the etiology of rheumatoid arthritis. The clinical manifestations of arthritis are different in each patients. In addition, the development of the medication is still continue to achieve the most effective role with less side effect. Nanoparticles may be the answer to this problem, since they have been widely used to improve the pharmacokinetic and pharmacodynamics of rheumatoid arthritis drugs. Using nanoparticles-tagged folate or PEG to deliver rheumatoid arthritis drugs may increase the specificity of the drugs to the target and consequently, may decrease the side effects of the drugs. The purpose of this review is to summarize the etiology, clinical manifestation and highlighting the use of nanoparticles in rheumatoid arthritis treatment.




Chabib, L., Ikawati, Z., Martien, R., Ismail, H., Wahyudi, M. D. P., Arimurni, D. A., … Hidayat, A. (2018). Rheumatoid arthritis and the challenge of using nanoparticles for its treatment. In MATEC Web of Conferences (Vol. 154). EDP Sciences. https://doi.org/10.1051/matecconf/201815404005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free